Safety of Direct Oral Anticoagulants for Gastrointestinal Hemorrhage in Patients With Nonvalvular Atrial Fibrillation
- 15 November 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 57 (10) , 1045-1053
Abstract
Goals and Background: Since the introduction of Direct Oral Anticoagulants (DOACs), “real-world” studies have investigated their safety profile on gastrointestinal hemorrhage (GIH) when used by patients with Non-Valvular Atrial Fibrillation. We performed a systematic review and meta-analysis to compile and summarize this data after Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Study: Medline and Embase were systematically searched until April 2021. Observational studies that met predefined inclusion criteria were included and hazard ratios (HRs) with 95% CI were extracted. Subgroup analyses based on DOAC doses, history of chronic kidney disease, stroke, prior exposure to VKA (vitamin K antagonist), age, gender, geographic location of population samples, as well as Leave-One-Out and Low/Moderate Risk of Bias sensitivity analyses were performed. A random effects model was used. Results: A total of 46 studies were included. Apixaban was associated with a reduced risk of GIH compared with Dabigatran (HR: 0.67, 95% CI, 0.56 to 0.81, I 2: 53.28%), Rivaroxaban (HR: 0.56, 95% CI, 0.44 to 0.70, I 2: 79.17%), and VKA (HR: 0.68, 95% CI, 0.60 to 0.78, I 2: 71.93%). Rivaroxaban was associated with increased GIH risk compared with Dabigatran (HR: 1.19, 95% CI, 1.02 to 1.40, I 2: 72.96%) and VKA (HR: 1.16, 95% CI, 1.05 to 1.27, I 2: 81.95%). Dabigatran was associated with similar GIH risk compared with VKA (HR: 1.11, 95% CI, 0.98 to 1.26, I 2: 87.28%). Conclusions: Our study shows that Apixaban was associated with a reduction in GIH risk compared with Dabigatran, Rivaroxaban and VKA, whereas Rivaroxaban was associated with an increase in GIH risk compared with both Dabigatran and VKA.Keywords
This publication has 24 references indexed in Scilit:
- National Trends in Ambulatory Oral Anticoagulant UseThe American Journal of Medicine, 2015
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2013
- Atrial Fibrillation, Stroke Risk, and Warfarin Therapy RevisitedStroke, 2013
- Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult PopulationThe American Journal of Cardiology, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluationInternational Journal of Epidemiology, 2008
- Management of Newly Detected Atrial Fibrillation: A Clinical Practice Guideline from the American Academy of Family Physicians and the American College of PhysiciansAnnals of Internal Medicine, 2003